Kazanietz Marcelo G, Caloca Maria J
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas, Universidad de Valladolid, Valladolid, Spain.
Cancer Res. 2017 Oct 15;77(20):5445-5451. doi: 10.1158/0008-5472.CAN-17-1456. Epub 2017 Aug 14.
Rho family GTPases are critical regulators of cellular functions that play important roles in cancer progression. Aberrant activity of Rho small G-proteins, particularly Rac1 and their regulators, is a hallmark of cancer and contributes to the tumorigenic and metastatic phenotypes of cancer cells. This review examines the multiple mechanisms leading to Rac1 hyperactivation, particularly focusing on emerging paradigms that involve gain-of-function mutations in Rac and guanine nucleotide exchange factors, defects in Rac1 degradation, and mislocalization of Rac signaling components. The unexpected pro-oncogenic functions of Rac GTPase-activating proteins also challenged the dogma that these negative Rac regulators solely act as tumor suppressors. The potential contribution of Rac hyperactivation to resistance to anticancer agents, including targeted therapies, as well as to the suppression of antitumor immune response, highlights the critical need to develop therapeutic strategies to target the Rac pathway in a clinical setting. .
Rho家族GTP酶是细胞功能的关键调节因子,在癌症进展中发挥重要作用。Rho小G蛋白,特别是Rac1及其调节因子的异常活性是癌症的一个标志,并促成癌细胞的致瘤和转移表型。本综述探讨了导致Rac1过度激活的多种机制,特别关注涉及Rac和鸟嘌呤核苷酸交换因子功能获得性突变、Rac1降解缺陷以及Rac信号成分错误定位的新范式。Rac GTP酶激活蛋白意外的促癌功能也挑战了这些负性Rac调节因子仅作为肿瘤抑制因子的传统观念。Rac过度激活对包括靶向治疗在内的抗癌药物耐药性以及对抗肿瘤免疫反应抑制的潜在影响,凸显了在临床环境中开发靶向Rac途径治疗策略的迫切需求。